nach oben

Journal of Inherited Metabolic Disease

Erschienen in:

01.07.2012 | SSIEM Symposium 2011

Newborn screening for lysosomal storage diseases: an ethical and policy analysis

verfasst von: Lainie Friedman Ross

Erschienen in: Journal of Inherited Metabolic Disease | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

The traditional focus of newborn screening (NBS) is testing infants for medical conditions like phenylketonuria (PKU) that may cause significant morbidity or mortality unless treatment is initiated early. Although the Wilson and Jungner criteria were not designed specifically for NBS, the public health screening criteria have been used, with some modifications, to justify what conditions are included in a universal NBS panel. These criteria are being challenged by platform technologies like tandem mass spectrometry (MS/MS) that allow for the identification of numerous conditions on a single sample because they identify many conditions and variants simultaneously, some of which meet and others which fail to meet the criteria. In this manuscript, I evaluate three lysosomal storage diseases included in this multiplex screening test—Pompe disease, Fabry disease, and Krabbe disease. I show that they fail to meet some of the critical Wilson and Jungner criteria and thus are not ready for inclusion in universal NBS panels. Rather, screening for these conditions should only be performed in the research context with institutional review board approval and parental permission.

Alexander D, van Dyck PC (2006) A vision of the future of newborn screening. Pediatr 117(5 Pt 2):S350–S354

American Academy of Pediatrics (AAP) Committee on Bioethics (2001) Ethical issues with genetic testing in pediatrics. Pediatr 107:1451–1455CrossRef

Andermann A, Blancquaert I, Beauchamp S, Dery V (2008) Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bulletin World Health Org 86(4):317–319CrossRef

Andrews LL, Fullarton JE, Holtzman NA, Motulsky AG, and the Committee on Assessing Genetic Risks, Institute of Medicine (IOM) (eds) (1994) Assessing genetic risks: implications for health and social policy. National Academy Press, Washington, DC

Arnold GL, VanHove J, Freedenberg D et al. (2009) A Delphi clinical practice protocol for the management of very long chain acyl-CoA dehydrogenase deficiency. Mol Gen Metab 96:85–90CrossRef

ASHG/ACMG American Society of Human Genetics (ASHG)/American College of Medical Genetics (ACMG) (1995) Points to consider: ethical, legal, and psychosocial implications of genetic testing in children and adolescents. Amer J Hum Genet 57:1233–1241

Bailey DB, Beskow LM, Davis AM, Skinner D (2006) Changing perspectives on the benefits of newborn screening. Mental Retard Develop Disabil Res Rev 12:270–279CrossRef

Bashore L (2004) Childhood and adolescent cancer survivors' knowledge of their disease and effects of treatment. J Pediatric Onc Nurs 21:98–102CrossRef

Canadian Paediatric Society (CPS) Bioethics Committee and the Ethics and Public Policy Committee, Canadian College of Medical Geneticists (2003) Guidelines for genetic testing of healthy children. Paediatr Child Health 8(1):42–45, Reaffirmed February 2010

Caniglia M, Rana I, Pinto RM et al. (2002) Allogeneic bone marrow transplantation for infantile globoid-cell leukodystrophy (Krabbe's disease). Pediatr Transplant 6(5):427–431PubMedCrossRef

Chakrapani A, Vellodi A, Robinson P, Jones S, Wraith JE (2010) Treatment of infantile Pompe disease with alglucosidase alpha: the UK experience. J Inherit Metab Dis 33:747–750PubMedCrossRef

Chen LR, Chen CA, Chiu SN et al. (2009) Reversal of cardiac dysfunction after enzyme replacement in patients with infantile-onset Pompe disease. J Pediatr 155:271–275PubMedCrossRef

Chien YH, Chiang SC, Zhang XK et al. (2008) Early detection of Pompe disease by newborn screening is feasible: results from the Taiwan screening program. Pediatr 122(1):e39–e45CrossRef

Chien YH, Lee NC, Huang HJ, Thurberg BL, Tsai FJ, Hwu WL (2011) Later-Onset Pompe disease: early detection and early treatment initiation enabled by newborn screening. J Pediatr 158:1023–1027PubMedCrossRef

Dajnoki A, Muhl A, Fekete G et al. (2008) Newborn screening for Pompe disease by measuring GAA activity using tandem mass spectrometry. Clin Chem 54:1624–1629PubMedCrossRef

Duffner PK, Caggana M, Orsini JJ et al. (2009a) Newborn screening for Krabbe disease: the New York State model. Pediatr Neurol 40:245–252, discussion 253-5PubMedCrossRef

Duffner PK, Jalal K, Carter RL (2009b) The hunger’s hope Krabbe family database. Pediatr Neurol 40:13–18PubMedCrossRef

Duffner PK, Caviness VS, Erbe RW et al. (2009c) The long-term outcomes of presymptomatic infants transplanted for Krabbe disease: report of the workshop held on July 11 and 12, 2008, Holiday Valley, New York. Genet Med 11:450–454PubMedCrossRef

Erbe RW, Levy HL (2012) Neonatal screening. In: Rimoin DL, Connor JM, Pyeritz RE, Korf BR (eds) Emery and Rimoin's principles and practice of medical genetics, 6th edition, in press

Escolar ML, Poe MD, Provenzale JM et al. (2005) Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease. N Engl J Med 352:2069–2081PubMedCrossRef

Fuller M, Lovejoy M, Brooks DA, Harkin ML, Hopwood JJ, Meikle PJ (2004) Immunoquantification of alpha-galactosidase: evaluation for the diagnosis of Fabry disease. Clin Chem 50:1979–1985PubMedCrossRef

Gibson KM, Bennett MJ, Naylor EW, Morton DH (1998) 3-Methylcrotonyl-coenzyme A carboxylase deficiency in Amish/Mennonite adults identified by detection of increased acylcarnitines in blood spots of their children. J Pediatr 132(3 Pt 1):519–523PubMed

Hanley WB (2008) Finding the fertile woman with phenylketonuria. Europ J Obstet Gynec Repro Bio 137:131–135CrossRef

Hoffmann B (2009) Fabry disease: recent advances in pathology, diagnosis, treatment and monitoring. Orphanet J Rare Dis (OJRD) 4(21):1–9

Hopkin RJ, Bissler J, Banikazemi M et al. (2008) Characterization of Fabry disease in 352 pediatric patients in the Fabry registry. Pediatr Res 64(5):550–555PubMedCrossRef

Hwu WL, Chien YH, Lee NC et al. (2009) Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A). Hum Mutat 30:1397–1405PubMedCrossRef

Kemper AR, Hwu W-L, Lloyd-Puryear M, Kishnani PS (2007) Newborn screening for Pompe disease: synthesis of the evidence and development of screening recommendations. Pediatr 120:e1327–e1334CrossRef

Kemper AR, Knapp AA, Green NS, Comeau AM, Metterville DR, Perrin JM (2010) Weighing the evidence for newborn screening for early-infantile Krabbe disease. Genet Med 12:539–543PubMedCrossRef

Kishnani PS, Howell RR (2004) Pompe disease in infants and children. J Pediatr 144(5 Suppl):S35–S43PubMed

Kishnani PS, Hwu WL, Mandel H, Nicolino M, Yong F, Corzo D, for the Infantile-Onset Pompe Disease Natural History Study Group (2006) A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr 148:671–6PubMedCrossRef

Kishnani PS, Corzo D, Nicolonio M et al. (2007) Recombinant human acid alpha-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurol 68:99–109CrossRef

Kishnani PS, Goldenberg PC, DeArmey SL et al. (2010) Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab 99:26–33PubMedCrossRef

Kokotos F (2009) The vulnerable child syndrome. Pediatr Rev 30:193–194PubMedCrossRef

Krivit W, Shapiro EG, Peters C et al. (1998) Hematopoietic stem-cell transplantation in globoid-cell leukodystrophy. N Engl J Med 338:1119–1126PubMedCrossRef

Kumamoto S, Katafuchi T, Nakamura K et al. (2009) High frequency of acid alpha-glucosidase pseudodeficiency complicates newborn screening for glycogen storage disease type II in the Japanese population. Mol Gen Metab 97:190–195CrossRef

Labrousse P, Chien YH, Pomponio RJ et al. (2010) Genetic heterozygosity and pseudodeficiency in the Pompe disease newborn screening pilot program. Mol Genet Metab 99:379–383PubMedCrossRef

Li Y, Scott CR, Chamoles NA et al. (2004) Direct multiplex assay of lysosomal enzymes in dried blood spots for newborn screening. Clin Chem 50:1785–1796PubMedCrossRef

Linthorst GE, Vedder AC, Aerts JM, Hollak CE (2005) Screening for Fabry disease using whole blood spots fails to identify one-third of female carriers. Clin Chim Acta 353(1–2):201–203PubMedCrossRef

Linthorst GE, Bouwman MG, Wijburg FA, Aerts JM, Poorthuis BJ, Hollak CE (2010) Screening for Fabry disease in high-risk populations: a systematic review. J Med Genet 47:217–222PubMedCrossRef

Meikle PJ, Grasby DJ, Dean CJ et al. (2006) Newborn screening for lysosomal storage disorders. Mol Genet Metab 88:307–314PubMedCrossRef

Mendelsohn NJ, Messinger YHH, Rosenberg AS, Kishnani PS (2009) Elimination of antibodies to recombinant enzyme in Pompe's disease. N Eng J Med 360:194–195CrossRef

Mercimek-Mahmutoglu S, Moeslinger D, Haberle J et al. (2010) Long-term outcome of patients with argininosuccinate lyase deficiency diagnosed by newborn screening in Austria. Mol Genet Metab 100:24–28PubMedCrossRef

Merk T, Wibmer T, Schumann C, Kruger S (2009) Glycogen storage disease type II (Pompe disease)–influence of enzyme replacement therapy in adults. Europ J Neurol 16:274–277CrossRef

Moyer VA, Calonge N, Teutsch SM, Botkin JR, on behalf of the United States Preventive Task Force (2008) Expanded newborn screening: process, policy and priorities. Hast Cent Rep 38(3):32–39CrossRef

National Screening Committee (UK) (2011) Programme appraisal criteria: Criteria for appraising the viability, effectiveness and appropriateness of a screening programme. On the web at: http://www.screening.nhs.uk/criteria. Last accessed November 25, 2011

Newborn Screening Task Force (2000) Serving the family from birth to the medical home: newborn screening: a blueprint for the future—a call for a National Agenda on State Newborn Screening Programs. Pediatr 106(2 Suppl):389–422

Petros M (2011) Revisiting the Wilson-Jungner criteria: how can supplemental criteria guide public health in the era of genetic screening? Genet Med. doi:10.1097/GIM.0b013e31823331d0

President’s Council on Bioethics (2008) The changing moral focus of newborn screening. Government Printing Office, Washington DC

Rohrbach M, Klein A, Kohli-Wiesner A et al. (2010) CRIM-negative infantile Pompe disease: 42-month treatment outcome. J Inherit Metab Dis 33:751–757PubMedCrossRef

Ross LF (2006) Screening for conditions that do not meet the Wilson and Jungner criteria: the case of Duchenne muscular dystrophy. Amer J Med Genet 140A:914–922CrossRef

Ross LF (2010) Mandatory versus voluntary consent for newborn screening? Kennedy Instit Ethics J 20:299–328

Rozenfeld PA (2009) Treatment and diagnosis. IUBMB (Internat Union Biochem Mol Bio) Life 61(11):1043–1050CrossRef

Saito S, Ohno K, Sakuraba H (2011) Fabry-database.org: database of the clinical phenotypes, genotypes and mutant alpha-galactosidase structures in Fabry disease. J Human Genet 56:467–468CrossRef

Salveson R (2011) Expansion of the New York State newborn screening panel and Krabbe disease: a systematic program evaluation. PhD Dissertation for the School of Nursing at Columbia University. On the web at: http://academiccommons.columbia.edu/catalog/ac:132317. Last accessed November 25, 2011

Spada M, Pagliardini S, Yasuda M et al. (2006) High incidence of later-onset Fabry disease revealed by newborn screening. Amer J Hum Genet 79:31–40PubMedCrossRef

Strothotte S, Strigl-Pill N, Grunert B et al. (2010) Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial. J Neurol 257:91–97PubMedCrossRef

Timmermans S, Buchbinder M (2010) Patients-in-waiting: living between sickness and health. J Health Social Behav 51:408–423CrossRef

van Calcar SC, Gleason LA, Lindh H et al. (2007) 2-Methylbutyryl-CoA dehydrogenase deficiency in Hmong infants identified by expanded newborn screen. Wisconsin Med J 106(1):12–15

Wilcken B (2010) Expanded newborn screening: reducing harm, assessing benefit. J Inherit Metab Dis 33(Suppl 2):S205–S210PubMedCrossRef

Wilson JM, Jungner G (1968) Principles and practice of screening for disease. Public health papers 34. World Health Organization, Geneva, pp 1–163

Working Party of the Clinical Genetics Society (UK) (1994) The genetic testing of children. J Med Genet 31:785–797CrossRef

Titel: Newborn screening for lysosomal storage diseases: an ethical and policy analysis
verfasst von: Lainie Friedman Ross
Publikationsdatum: 01.07.2012
Verlag: Springer Netherlands
Erschienen in: Journal of Inherited Metabolic Disease / Ausgabe 4/2012
Print ISSN: 0141-8955
Elektronische ISSN: 1573-2665
DOI: https://doi.org/10.1007/s10545-011-9435-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Nierenkarzinom | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Newborn screening for lysosomal storage diseases: an ethical and policy analysis

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2012

Progress in understanding 2-hydroxyglutaric acidurias

Improving test properties for neonatal cystic fibrosis screening in the Netherlands before the nationwide start by May 1st 2011

Gene therapy for metabolic disorders: an overview with a focus on urea cycle disorders

Creatine and guanidinoacetate transport at blood-brain and blood-cerebrospinal fluid barriers

Mitochondrial proteomics—a tool for the study of metabolic disorders

Newborn screening programmes in Europe; arguments and efforts regarding harmonization. Part 2 – From screening laboratory results to treatment, follow-up and quality assurance

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Update Innere Medizin